Last reviewed · How we verify
AT1 blocker candesartan
AT1 blocker candesartan is a Angiotensin II receptor blocker (ARB) Small molecule drug developed by The Netherlands Cancer Institute. It is currently in Phase 3 development for Cancer (specific indication under investigation in phase 3 trial at The Netherlands Cancer Institute).
Candesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.
Candesartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Cancer (specific indication under investigation in phase 3 trial at The Netherlands Cancer Institute).
At a glance
| Generic name | AT1 blocker candesartan |
|---|---|
| Sponsor | The Netherlands Cancer Institute |
| Drug class | Angiotensin II receptor blocker (ARB) |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Candesartan is an angiotensin II receptor antagonist that selectively binds to AT1 receptors on vascular smooth muscle and other tissues, blocking the effects of angiotensin II. This prevents vasoconstriction, reduces aldosterone secretion, and decreases sodium reabsorption, leading to vasodilation and blood pressure reduction. In the context of The Netherlands Cancer Institute's phase 3 trial, AT1 blockade may be investigated for potential anti-angiogenic or immunomodulatory effects in cancer treatment.
Approved indications
- Cancer (specific indication under investigation in phase 3 trial at The Netherlands Cancer Institute)
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Hypotension
Key clinical trials
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (PHASE4)
- Evaluating the Effect of Candesartan vs Placebo in Prevention of Trastuzumab-associated Cardiotoxicity (PHASE3)
- Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker (NA)
- Effects of Sodium Intake on (PK/PD) Relationship of a Single Dose of a Renin Angiotensin System-Blocker (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AT1 blocker candesartan CI brief — competitive landscape report
- AT1 blocker candesartan updates RSS · CI watch RSS
- The Netherlands Cancer Institute portfolio CI
Frequently asked questions about AT1 blocker candesartan
What is AT1 blocker candesartan?
How does AT1 blocker candesartan work?
What is AT1 blocker candesartan used for?
Who makes AT1 blocker candesartan?
What drug class is AT1 blocker candesartan in?
What development phase is AT1 blocker candesartan in?
What are the side effects of AT1 blocker candesartan?
What does AT1 blocker candesartan target?
Related
- Drug class: All Angiotensin II receptor blocker (ARB) drugs
- Target: All drugs targeting AT1 receptor (Angiotensin II type 1 receptor)
- Manufacturer: The Netherlands Cancer Institute — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Cancer (specific indication under investigation in phase 3 trial at The Netherlands Cancer Institute)
- Compare: AT1 blocker candesartan vs similar drugs
- Pricing: AT1 blocker candesartan cost, discount & access